Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 250

1.

Representativeness of RELAX-AHF clinical trial population in acute heart failure.

Wang TS, Hellkamp AS, Patel CB, Ezekowitz JA, Fonarow GC, Hernandez AF.

Circ Cardiovasc Qual Outcomes. 2014 Mar;7(2):259-68. doi: 10.1161/CIRCOUTCOMES.113.000418. Epub 2014 Mar 4.

2.

Design of the RELAXin in acute heart failure study.

Ponikowski P, Metra M, Teerlink JR, Unemori E, Felker GM, Voors AA, Filippatos G, Greenberg B, Teichman SL, Severin T, Mueller-Velten G, Cotter G, Davison BA.

Am Heart J. 2012 Feb;163(2):149-55.e1. doi: 10.1016/j.ahj.2011.10.009.

PMID:
22305830
3.

Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.

Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR; RELAX-AHF Investigators..

J Am Coll Cardiol. 2013 Jan 15;61(2):196-206. doi: 10.1016/j.jacc.2012.11.005.

4.

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.

Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M; RELAXin in Acute Heart Failure (RELAX-AHF) Investigators..

Lancet. 2013 Jan 5;381(9860):29-39. doi: 10.1016/S0140-6736(12)61855-8. Epub 2012 Nov 7.

PMID:
23141816
5.

Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.

Felker GM, Teerlink JR, Butler J, Hernandez AF, Miller AB, Cotter G, Davison BA, Filippatos G, Greenberg BH, Ponikowski P, Voors AA, Hua TA, Severin TM, Unemori E, Metra M.

J Am Coll Cardiol. 2014 Oct 14;64(15):1591-8. doi: 10.1016/j.jacc.2014.05.071.

6.

Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial.

Filippatos G, Teerlink JR, Farmakis D, Cotter G, Davison BA, Felker GM, Greenberg BH, Hua T, Ponikowski P, Severin T, Unemori E, Voors AA, Metra M.

Eur Heart J. 2014 Apr;35(16):1041-50. doi: 10.1093/eurheartj/eht497. Epub 2013 Dec 6.

7.

Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.

Ghosh RK, Banerjee K, Tummala R, Ball S, Ravakhah K, Gupta A.

Cardiovasc Ther. 2017 Feb;35(1):55-63. doi: 10.1111/1755-5922.12231. Review.

PMID:
27727514
8.

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF.

Metra M, Ponikowski P, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Hua TA, Severin T, Unemori E, Voors AA, Teerlink JR.

Eur Heart J. 2013 Oct;34(40):3128-36. doi: 10.1093/eurheartj/eht371. Epub 2013 Sep 2.

9.

Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study.

Cotter G, Voors AA, Prescott MF, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Milo O, Hua TA, Qian M, Severin TM, Teerlink JR, Metra M, Davison BA.

Eur J Heart Fail. 2015 Nov;17(11):1133-43. doi: 10.1002/ejhf.331. Epub 2015 Sep 3.

10.

Serelaxin : a potential new drug for the treatment of acute heart failure.

Neverova N, Teerlink JR.

Expert Opin Investig Drugs. 2014 Jul;23(7):1017-26. doi: 10.1517/13543784.2014.924504. Epub 2014 May 28. Review.

PMID:
24865798
11.

Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.

Liu LC, Voors AA, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Chen Y, Greenberg BH, Ponikowski P, Pang PS, Prescott MF, Hua TA, Severin TM, Metra M.

Clin Res Cardiol. 2016 Sep;105(9):727-37. doi: 10.1007/s00392-016-0979-8. Epub 2016 Mar 26.

12.

How does a clinical trial fit into the real world? The RELAX-AHF study population into the EAHFE registry.

Miró Ò, Gil V, Müller C, Mebazaa A, Bueno H, Martín-Sánchez FJ, Herrero P, Jacob J, Llorens P.

Clin Res Cardiol. 2015 Oct;104(10):850-60. doi: 10.1007/s00392-015-0854-z. Epub 2015 Apr 24.

PMID:
25903109
13.

Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF.

Voors AA, Davison BA, Felker GM, Ponikowski P, Unemori E, Cotter G, Teerlink JR, Greenberg BH, Filippatos G, Teichman SL, Metra M; Pre-RELAX-AHF study group..

Eur J Heart Fail. 2011 Sep;13(9):961-7. doi: 10.1093/eurjhf/hfr060. Epub 2011 May 28.

14.

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.

Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E, Teichman SL, Cotter G.

Lancet. 2009 Apr 25;373(9673):1429-39. doi: 10.1016/S0140-6736(09)60622-X. Epub 2009 Mar 28.

PMID:
19329178
15.

Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies.

Davison BA, Metra M, Cotter G, Massie BM, Cleland JG, Dittrich HC, Edwards C, Filippatos G, Givertz MM, Greenberg B, Ponikowski P, Voors AA, O'Connor CM, Teerlink JR; PROTECT and RELAX-AHF Executive Committees..

JACC Heart Fail. 2015 May;3(5):395-403. doi: 10.1016/j.jchf.2015.01.007.

PMID:
25951761
16.

Recent developments in the treatment of heart failure: highlights from the American Heart Association's Scientific Sessions, Los Angeles, California, 3 - 7 December 2012.

von Haehling S.

Expert Opin Investig Drugs. 2013 Jul;22(7):933-7. doi: 10.1517/13543784.2013.798301. Epub 2013 May 9.

PMID:
23656525
17.

Acute heart failure registry from high-volume university hospital ED: comparing European and US data.

Karasek J, Widimsky P, Ostadal P, Hrabakova H, Penicka M.

Am J Emerg Med. 2012 Jun;30(5):695-705. doi: 10.1016/j.ajem.2011.03.027. Epub 2011 Jun 8.

PMID:
21641150
18.

Serelaxin a novel treatment for acute heart failure.

Castrini AI, Carubelli V, Lazzarini V, Bonadei I, Lombardi C, Metra M.

Expert Rev Clin Pharmacol. 2015;8(5):549-57. doi: 10.1586/17512433.2015.1073587. Review.

PMID:
26294074
19.

Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry.

Spinar J, Parenica J, Vitovec J, Widimsky P, Linhart A, Fedorco M, Malek F, Cihalik C, Spinarová L, Miklik R, Felsoci M, Bambuch M, Dusek L, Jarkovsky J.

Crit Care. 2011;15(6):R291. doi: 10.1186/cc10584. Epub 2011 Dec 7.

20.

Long-term survival after hospitalization for acute heart failure--differences in prognosis of acutely decompensated chronic and new-onset acute heart failure.

Lassus JP, Siirilä-Waris K, Nieminen MS, Tolonen J, Tarvasmäki T, Peuhkurinen K, Melin J, Pulkki K, Harjola VP; FINN-AKVA study group..

Int J Cardiol. 2013 Sep 20;168(1):458-62. doi: 10.1016/j.ijcard.2012.09.128. Epub 2012 Oct 13.

PMID:
23073273

Supplemental Content

Support Center